Feasibility of the preventive use of vibration training as a prophylaxis of chemotherapy-induced peripheral neuropathy

Feasibility of the preventive use of vibration training as a prophylaxis of chemotherapy-induced peripheral neuropathy - PräViC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00030396

Enrollment

Registered

2022-10-04

Start date

2023-03-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C97

Interventions

Group 1: Standardised movement therapy intervention on the vibration plate: - 2x/week for 20 - 30 minutes each - accompanying chemotherapy, over the entire period, but for a maximum of 24 weeks Group

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: - Age = 18 - 69 years - Patients who are about to receive a potentially neurotoxic oncological therapy for the first time

Exclusion criteria

Exclusion criteria: - Patients with pre-existing neuropathy from other causes such as diabetes mellitus or from harmful alcohol consumption. - with chemotherapy already received - severe acute neurological, neuromuscular or degenerative diseases - disturbance of the vestibular system - any metal implants (vibration plate) - thrombocytopenia with a platelet count <20,000/µl - acute thrombosis or embolism within the last 12 months - acute bleeding or severe bleeding tendency (independent of platelet count) - Incomplete wound healing (contraindication for local loading of the affected structure and whole-body loading) - Presence of osseous metastases/intactness - All disease situations that do not permit sporting activity, in particular: o Clinically manifest heart failure (NYHA III-IV). o Respiratory partial or global insufficiency o Symptomatic CHD o Severe refractory hypertension o Uncontrollable COPD o Uncontrolled cerebral seizures - Participation in another exercise study

Design outcomes

Primary

Measure	Time frame
Is to test the feasibility of the preventive use of vibration training during chemotherapeutic treatment on the development of CIPN, measured by the neurological condition (Total Neuropathy Sore) and CIPN symptoms (FACT Gog-Ntx & EORTC QLQ-CIPN20).	—

Secondary

Measure	Time frame
1.) to maintain or increase subjective quality of life as measured by the EORTC QLQ-C30 questionnaire 2) the prevention of CIPN associated pain as measured by the painDETECT questionnaire	—

Countries

Germany

Contacts

Public ContactAnne Kollikowski

Universitätsklinikum Würzburg; Comprehensive Cancer Center Mainfranken / Komplementäre Onkologie Integrativ (KOI)

kollikows_a1@ukw.de+4993120135350

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026